Gilead to launch generic versions of its hepatitis drugs

(Reuters) - Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.The drugmaker's generic version of drugs such as Harvoni and Epclusa, which raked in combined sales of $831 million in the quarter ended June 30, will be launched via a newly created subsidiary Asegua Therapeutics LLC.Gilead's decision comes more than a month after the U.S. Food and Drug Administration ap